Latest Conference Coverage
Improvements in Treating Narcolepsy, Idiopathic Hypersomnia Through Xywav
July 2nd 2022Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.
Regularly Measuring Cognition in MS, and Treating Cognitive Issues: John DeLuca, PhD
July 1st 2022The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]
Benefits From the 2022 ATMRD Congress and Multidisciplinary Teams: Laxman Bahroo, DO
June 30th 2022The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 3 minutes]
Awareness of Botulinum Toxins in the Movement Disorder Landscape: Laxman Bahroo, DO
June 29th 2022The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]
Evobrutinib, BTK Inhibitors, and the Associations With Neurofilament Light: Jens Kuhle, MD, PhD
June 27th 2022The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]
Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH
June 25th 2022The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
June 24th 2022The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]
Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease
June 23rd 2022After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.
The ATMRD Congress and Importance of Accessibility as a Clinician: Jill Farmer, DO, MPH
June 23rd 2022The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]
The Potential of Targeting Anti-CD3 in Progressive Multiple Sclerosis: Tanuja Chitnis, MD
June 22nd 2022The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]
Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom
June 22nd 2022The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics
June 20th 2022After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
Highlights of the Advanced Therapeutics in Movement and Related Disorders Congress: Jean Hubble, MD
June 19th 2022The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]
The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies
June 19th 2022In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Perspectives From a Neurology Career in Industry and Academia: Jean Hubble, MD
June 19th 2022Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]
Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease
June 18th 2022A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.
